OR WAIT null SECS
© 2023 MJH Life Sciences and BioPharm International. All rights reserved.
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
November 06, 2023
Dujuan Lu, PhD, global leader—E&L, SGS Health Sciences, talks about the differences in designing E&L testing for combination products vs. conventional pharmaceuticals.
November 03, 2023
Dujuan Lu, PhD, global leader—E&L, SGS Health Sciences, recommends some key issues that pharma manufacturers should consider when formulating products that require a medical device.
September 26, 2023
Under a new pact, Genentech and PeptiDream will collaborate to discover and develop novel peptide-radioisotope drug conjugates.
May 31, 2023
API supplier Olon has started construction of a new manufacturing facility in Milan, Italy, which will be dedicated to production of cytotoxic payloads and linkers for ADCs.
March 06, 2023
The guidance is intended to build on the existing International Council for Harmonisation (ICH) quality guidance.
November 02, 2022
Learning from early market failures, the biopharma industry has worked to improve the fate of antibody drug conjugates.
June 27, 2022
ImmunoGen has formed a research collaboration with Oxford BioTherapeutics to develop novel antibody-drug conjugates for cancers with high unmet needs.
May 15, 2022
The author describes how to seize market opportunities while navigating the requirements of both drug therapies and delivery devices.
February 11, 2022
Piramal Pharma Solutions plans to construct a multipurpose ADC manufacturing and aseptic fill/finish facility in Grangemouth, Scotland, and to upgrades its existing API manufacturing facility in Morpeth, England.
November 02, 2021
ADC development is on a positive trajectory from a deeper understanding of therapeutic mechanisms and technological advances.